DIA Singapore Annual Meeting 2026

Advancing Sustainable Innovation in Asia: Navigating the Future of Regulatory and Clinical Frontiers

16-17 September 2026
One Farrer Hotel, Singapore

Overview

The DIA Singapore Annual Meeting 2026 will be held on 16–17 September 2026 under the theme "Sustainable Innovation for Tomorrow - Advancing Regulatory and Clinical Frontiers to Accelerate Patient Access in Asia."

Drug development and healthcare innovation in Asia are rapidly evolving, driven by regulatory convergence, digital transformation, and the adoption of advanced clinical methodologies. As countries across the region work toward harmonization and more efficient approval pathways, there is a growing need for alignment between regulatory frameworks and clinical operations.

The meeting will bring experts from regulatory authorities, industry, and academia to explore key developments shaping the future of healthcare in Asia. Through discussions on modern trial modalities, regulatory innovation, and next-generation technologies, participants will gain insights into how to accelerate patient access while maintaining data integrity, safety, and operational excellence.

In-depth discussions will focus on key topics such as:

- Regulatory convergence and reliance pathways across APAC and ASEAN
- Modern clinical trial modalities: RWD/RWE, DCT, IVD/MD, and innovative endpoints
- AI and digital transformation in regulatory affairs and clinical development
- Accelerating patient access through regulatory innovation and lifecycle strategies
- Next-generation clinical operations and technology-enabled trial execution

Join us to engage in meaningful dialogue, share best practices, and help shape a more connected, innovative, and patient-centered clinical and regulatory ecosystem across Asia.

Objective

Participants Participants will gain an enhanced understanding of major global regulatory developments in recent years. This insight will support proactive preparation for future changes and their implications in Asia, while broadening strategic perspectives.

The knowledge gained can be applied within organizations to inform clinical development strategies and regulatory submission planning.

Who should attend?

- Regulatory authorities
- Professionals in Clinical Research, Pharmacovigilance, Product Development, and Regulatory Affairs
- Academia, researchers and investigators for new drug development and regulatory science
- Patient associations
- Medical Affairs
- Professionals in Real World Data

GET MORE OUT OF SAM 2026 WITH MY DIA

Download My DIA to access the latest agenda, explore speakers and exhibitors, connect with fellow attendees, and stay up to date throughout the meeting.

App Store	Google Play

SCAN TO DOWNLOAD MY DIA

Program Chairs

Chair. Finny Liu, MSc, RPh
APAC Regional Regulatory Policy Lead, Roche

Co-Chair. Helene Sou, MSc, RAC
Global Regulatory Policy and Innovation, Takeda Pharmaceutical Company Limited

Program Committee

Sandy Chan
Director, Asia Pacific Leader, Global Regulatory Policy and Intelligence, Johnson & Johnson

Martin Lim, MBA
Co-Founder and CEO, ONWARD Health Research

Thean Soo Lo, BPharm(Hons), MSc
Regulatory Affairs Management Consultant, TS Consulting

Edana Loke
Director, JAPAC Regulatory Policy and Intelligence, AbbVie

Karin Markgraf, Phd
Head of Regulatory Affairs Asia Pacific, Merck Healthcare

Clare Tan
Global Project Management Director
Shanghai Henlius Biotech,

Huey Bee Pey
Executive Director, Project Management , Parexel International

Serene Ong
Founder, Phoenixus

Asha Thanabalan
Lead for Business development, Clinical Research Malaysia

Advisory Committee

Chair. Jing Ping YEO, PhD, MBA
VP, Clinical Solutions & Head, Asia Pacific, Precision for Medicine

Jack Wong
Founder, Asia Regulatory Professionals Association

Kum Cheun Wong, PharmD
Head Regulatory Policy Most of World Regulatory Affairs, GDD
Novartis Asia Pacific Pharmaceuticals Pte Ltd

Jin Shun, MBA
Head - Business Development & Regulatory Affairs, Pharmagend Global Medical Services Pte. Ltd.

Young Joo Park, MPH, PhD
Vice President, Korea, Singapore and SEA, DIA

The Drug Information Association, Inc.
DIA Global Center: Washington, DC, USA | Basel, Switzerland | Beijing, China | Horsham, PA, USA | Tokyo, Japan | Seoul, Korea | Mumbai, India

AGENDA | 16 September | Day 1 | ALL TIMINGS IN SGT

The title and speaker(s) are subject to change

8.00 – 8.45 am	Registration
8.45 – 9.00 am	**Opening Remarks**
	Young Joo Park, MPH, PhD, Vice President, Korea, Singapore and SEA, DIA
	Jingping Yeo,PhD, MBA, Chair, Advisory Committee, DIA Singapore
9.00 am – 12.00 pm	**Plenary Session -** **From Policy to Patient: Senior Regulators' Roadmap for Advancing Clinical and Regulatory Frontiers**
	As the healthcare landscape undergoes a rapid digital and biological transformation, the bridge between high-level policy and bedside care has never been more critical. In an era characterized by acceleration of science, AI-driven diagnostics, decentralized clinical trials, the rise of precision medicine, and technologies advances, regulatory bodies are no longer just "gatekeepers"—they are active architects of innovation and enablers. This plenary session brings together senior health authority leaders from across the region and beyond to share their vision for a robust, future-ready regulatory ecosystem. In the Plenary Panel Discussion, panelists will provide high-level updates on their respective strategic initiatives, focusing on bridging the gap between high-level policy and real-world patient access. Key Discussion Points: - The Evolution of Agility: How regulators are implementing collaborative reliance pathways and expedited programs to keep pace with the speed of scientific discovery. - Gene Therapy & Advanced Modalities: Navigating the unique global regulatory challenges of cell and gene therapies—from manufacturing consistency to long-term safety monitoring. - Sustainable Innovation: Strategies for aligning regional clinical trial frameworks to make Asia a primary destination for global drug development. - Digital Transformation: The regulatory perspective on integrating AI, Real-World Evidence (RWE), and Decentralized Clinical Trials (DCTs) into formal submission and review processes.
Session Chair	**Finny Liu, MSc, RPh** APAC Regional Regulatory Policy Lead Roche, Singapore **Helene Sou, MSc, RAC** Global Regulatory Policy and Innovation, Takeda Pharmaceutical Company Limited, Singapore
9.00 - 9.10 am	Introduction
9.10 - 9.30 am	**[Keynote Speech]** From Policy to Patient: Senior Regulators' Roadmap for Advancing Clinical and Regulatory Frontiers, Health Sciences Authority (HSA) Perspectives
	Adj Prof (Dr) Raymond Chua, Chief Executive Officer, Health Sciences Authority
9.30 - 9.50 am	From Policy to Patient: Senior Regulators' Roadmap for Advancing Clinical and Regulatory Frontiers, Medicines and Healthcare products Regulatory Agency (MHRA) Perspectives
	Lawrence Tallon, Chief Executive Officer, Medicines and Healthcare products Regulatory Agency (MHRA)
9.50 - 10.10 am	From Policy to Patient: Senior Regulators' Roadmap for Advancing Clinical and Regulatory Frontiers, Saudi Food and Drug Authority (SFDA) Perspectives
	H.E. Dr. Hisham Aljadhey, Chief Executive Officer, Saudi Food and Drug Authority (SFDA).
10.10 - 10.30 am	From Policy to Patient: Senior Regulators' Roadmap for Advancing Clinical and Regulatory Frontiers, African Medicines Agency (AMA) Perspectives
	Nathaniel Nkrumah, Senior Technical Officer, African Medicines Agency (AMA)
10.30 - 11.00 am	**Break**
11.00 am – 12.00 pm	Panel Discussion with Regulatory Agencies
	Moderator: **Leong Wai Yeen James, PhD,** Assistant Professor, Center of Regulatory Excellence, Duke- NUS Medical School Panelist: **- Adj Prof (Dr) Raymond Chua,** CEO, HSA **- Lawrence Tallon,** CEO, MHRA **- H.E. Dr. Hisham Aljadhey,** CEO, SFDA **- H.E. Dr. Delese Mimi Darko,** Director General, AMA
12.00 – 1.00 pm	**Lunch & Network**

AGENDA | 16 September | Day 1 | ALL TIMINGS IN SGT

The title and speaker(s) are subject to change

1.00 – 1.40 pm	**Sponsor's Innovation Hub**
1.00 - 1.20 pm	AI Optimization in Clinical Trials
	James Cheong, Senior Vice President - Asia Pacific, Precision for Medicine
1.20 - 1.40 pm	Innovation in Medicines Regulation: Accelerated SFDA Pathways by Development Stage
	Mohammed Jobran, CEO, PharmaKnowl Consulting
1.40 - 5.00 pm	**Session 1 - Modern Clinical Trials in APAC: From Concept to Implementation and Regulatory Adoption**
	In this session, we will explore how modern clinical trial modalities, including real-world data and evidence (RWD/RWE), decentralized trial elements (DCT), in vitro diagnostics and medical devices (IVD/MD), and innovative endpoints and study designs, are being considered, implemented, and accepted across the Asia-Pacific region. Regulatory evolution is central to this discussion. As APAC health authorities move toward more agile and harmonized frameworks at varying speeds, we will examine how innovative study designs can be aligned with diverse evidentiary requirements across markets without compromising safety and efficacy standards. Bringing together sponsors, research, sites, regulators, and technology partners, this session will examine how stakeholders are navigating the opportunities and practical challenges of adopting these approaches while ensuring data quality, patient safety, and operational feasibility. Through presentations and a panel discussion, we will highlight areas of alignment, identify key gaps, and discuss how to translate innovation into consistent, scalable practice, positioning APAC at the forefront of modern clinical trials.
Session Chair	**Karin Markgraf, PhD** Head of Regulatory Affairs Asia Pacific, Merck Healthcare **Martin Lim, MBA** Co-Founder and CEO ONWARD Health Research, **Sandy Chan** Director, Global Regulatory Policy and Intelligence, Johnson & Johnson
1.40 - 2.00 pm	Clinical trial development and adoption of innovative/modern clinical trial modalities in Singapore and the region.
	Eugene Gan, PhD., Senior Director, Operations, SCRI(Singapore Clinical Research Institute)
2.00 - 2.20 pm	The State of AI/ Technology in Clinical Trials: Today and Tomorrow
	Anastasia Miros, Partner, CFGI Consulting
2.20 - 2.40 pm	Supporting Innovation Earlier: An MHRA Perspective
	Anita Lim, PhD, Deputy Director, Innovation Accelerator, Science, Research & Innovation, MHRA
2.40 - 3.00 pm	Real-Time Clinical Trials (RTCTs): Exploring the Next Evolution in Clinical Development
	Dorothee Grimald, PhD., JAPAC Regulatory Policy Lead, Amgen
3.00 - 3.30 pm	**Break**
3.30 - 3.50 pm	Advancing Drug Development: Adaptive, Platform, Umbrella, and Hybrid Trial Designs with Real-World Data
	Parasar Pal, PhD., Head of Biostatistics and Clinical Measurement Sciences, Merck India
3.50 - 4.10 pm	Qualification of Novel Methodologies involving Digital Endpoints
	Cathelijne de Gram, EU regulatory policy leader, Global Regulatory Policy and Intelligence department, Johnson & Johnson
4.10 - 5.00 pm	Panel Discussion
5.00 - 5.15 pm	**Closing**

AGENDA | 17 September | Day 2 | ALL TIMINGS IN SGT

The title and speaker(s) are subject to change

7.30 – 8.00 am	Registration
8.00 - 9.00 am	**Spotlight on Access Consortium** **From Vision to Value: Unlocking Industry Opportunities through Access**
	Welcome and Opening Remarks by MHRA
	Lawrence Tallon, Chief Executive Officer, Medicines and Healthcare products Regulatory Agency (MHRA)
	HSA – The GROWTH Manifesto: What it Means for Industry
	Adj Prof (Dr) Raymond Chua, Chief Executive Officer, Health Sciences Authority
	TGA – Access in Practice: Delivering Predictability through Work-Sharing
	Anthony Lawler, Deputy Secretary, TGA
	Health Canada – Turning Strategy into Delivery: 2026 Action Plan Highlights
	Pamela Aung Thin, Assistant Deputy Minister, Health Canada
	Swissmedic – Industry in Focus: When and Why to Use Access
	Vincenza Trivigno, Executive Director, Swissmedic
	Open Forum and Q&A **- Lawrence Tallon,** MHRA **- Adj Prof (Dr) Raymond Chua,** HSA **- Andrew Simpson,** Assistant Secretary, Prescription Medicines Authorisation Branch, TGA **- Looi Yee Hoo**, Deputy Director, Therapeutic Products Branch, HSA
9.15 am – 12.45 pm	**Session 2-1 RA track (Parallel Session)** **Accelerating Access Through Regulatory Innovation and Convergence**
	Regulators across the region are working to balance faster access to innovative therapies with rigorous standards for quality, safety, and effectiveness. This session will explore how regulatory innovation, harmonization, and regional collaboration can support more efficient drug development and patient access in Asia, with discussions on topics including post-approval change convergence, collaborative assessments, combination products, and the use of AI in regulatory practices.
Session Chair	**Helene Sou, MSc, RAC** Global Regulatory Policy and Innovation, Takeda Pharmaceutical Company Limited, Singapore **Edana Loke** Director, JAPAC Regulatory Policy and Intelligence, AbbVie
9.15 - 9.30 am	Accelerating Access Through Regulatory Innovation in Taiwan
	Yu-Hsin Hsieh, PhD, Reviewer, Division of Medicinal Products, Taiwan Food and Drug Administration
9.30 - 9.45 am	EMA Experience in Reliance Pilots for Post-Authorisation Changes
	Evangelos Kotzagiorgis, Quality Specialist, European Medicines Agency
9.45 - 10.00 am	Breaking Barriers: Accelerating Multi-Product Change with PACMP, Reliance & EMA OPEN
	Suat Gnoh Por, Senior Regulatory Program Director, International Operations, Roche
10.00 - 10.15 am	Navigating Post-Approval Changes Across Asia-Pacific: Country-Specific Requirements
	Brix Bayuga, Director, Chemistry, Manufacturing, Controls/Devices, Global Regulatory Affairs-Asia Pacific, Eli Lilly
10.15 - 10.45 am	Panel Discussion
10.45 - 11.15 am	**Break**

11.15 - 11.35 am	Drug-Device Combination Products: Navigating Complexity Across Global Markets, Asia-Pacific focus
	Kai Yin Po, Principal Scientist, MSD
11.35 - 11.55 am	Singapore's approach to AI implementation
	Ivan KOH, Ministry of Health, Singapore
11.55 - 12.15 pm	AI in Regulatory Practice: Industry Use Cases
	Cameron Kieffer, PhD., Director, Global Regulatory Intelligence and Policy Research Takeda
12.15 - 12.30 pm	AI in Regulatory Practice: Use Cases in Korea MFDS
	Kyung Hun Son, PhD, Director, Drug Research Division, Pharmaceutical and Medical Device Research Development, MFDS
12.30 - 12.45 pm	Q&A

9.15 am – 12.45 pm

Session 2-2 Clinical Operations Track (Parallel Session)
Clinical Development Through Next-Generation Technologies: From Innovation to Scalable Execution

This session will offer a visionary glimpse into the future of clinical research through examining how stakeholders operationalize innovative technologies into sustainable, inspection-ready operations across APAC, bridging the gap between today's trials and tomorrow's tech-enabled ecosystems. Using examples and case studies, it will highlight practical experience transitioning from pilots to scalable delivery—while maintaining data quality, regulatory compliance, and reduced burden on sites and patients.

Session Chair

Martin Lim, MBA
Co-Founder and CEO
ONWARD Health Research

Clare Tan
Global Project Management Director
Shanghai Henlius Biotech

9.15 – 9.25 am	**Opening**
9.25 – 9.50 am	Healthcare AIX: Executive AI Strategy for Enterprise Transformation in the Agentic AI Era
	Shige(to) Miyamoto, Vice President, Digital Solutions APAC, Syneos Health
9.50 – 10.10 am	Digitising Clinical Trials: An Introduction to Digital Data Flow (DDF) Initiative
	Samit Jana, Lead Architect, Eli Lilly and Company, India
10.10 - 10.20 am	The Human Side of ePRO: Insights from a Clinical Trial Participant
	Muhammad Firdaus Bin Zainal Abidin, Clinical Trial Participant
10.20 - 10.45 am	AI Empowerment in Clinical Trial Institutions: Application and Exploration in Peking University Cancer Hospital
	Panjun GAO, Office Assistant, the National Drug Clinical Trial Institution (GCP Center), Peking University Cancer Hospital & Institute
10.45 - 11.15 am	**Break**
11.15 - 11.35 am	From Data Capture to Data Orchestration: Agentic AI as the Catalyst for Scalable Clinical Data in APAC
	Joydeep Sarkar , Director, Patient & Site Mediated Data Innovation & Incubation, IQVIA
11.35 - 11. 55 am	Navigating ICH GCP R3: Reimagining Trial Integrity through AI-Enabled Risk-Based Oversight
	Hyoback Lee, Team Lead, Solution Consulting – Korea, AP South & India, Medidata
11.55 - 12.45 pm	**Panel Discussion**
12.45 – 1.50 pm	**Lunch & Network**

1.50 – 2.10 pm	**Sponsor's Innovation Hub**
1:50 - 2:10 pm	Artificial Intelligence to Accelerate Clinical Trials and Evidence Generation in APAC
	Huren Sivaraj, CEO and Chief Medical Officer, Oncoshot Pte Ltd
2.10 - 3.40 pm	**Session 3- ASEAN Townhall** **Navigating Our Future, Together: Strengthening Regional Resilience and Harmonization for Sustainable Patient Access in ASEAN**
	The ASEAN region represents one of the world's most dynamic and diverse pharmaceutical markets. However, the complexity of varying national regulatory requirements often challenges the timely delivery of life-saving medicines. This Townhall serves as a collaborative forum for regulators, industry leaders, and healthcare stakeholders to discuss the unified path forward for the ASEAN Member States. Guided by the theme of Sustainable Patient Access, the session will explore how the region can move beyond individual regulatory silos toward a more resilient, harmonized ecosystem. Under the banner of "Navigating Our Future, Together," this session is structured around three strategic pillars designed to accelerate patient access. Regional Reliance (The "Together" Pillar)/ Regulatory Resilience (The "Future" Pillar)/ Clinical Frontier (The "Sustainable" Pillar)
Session Chair	**Finny Liu, MSc, RPh** APAC Regional Regulatory Policy Lead, Roche, Singapore **Thean Soo Lo, BPharm(Hons), MSc** Regulatory Affairs Management Consultant, TS Consulting
2.10 - 2.40 pm	Regional Reliance, Regulatory Resilience and the Clinical Frontier: An Industry View on Sustainable Access for ASEAN Patients
	Sia Lee Yoong, EFPIA ASEAN Network Representative, Global Regulatory Policy and Intelligence Manager, APAC, GlaxoSmithKline (GSK)
2.40 - 3.10 pm	Navigating Our Future Together, ASEAN perspectives in terms of Regional Reliance, Regulatory Resilience, and Clinical Frontier
	Azuana binti Ramli, RPh, PhD, Deputy Director General of Health (Pharmaceutical Services), Ministry of Health Malaysia
3.10 - 3.40 pm	Panel Discussion
	Moderator: **Kum Cheun Wong, PharmD** Head Regulatory Policy Most of World Regulatory Affairs, GDD Novartis Asia Pacific Pharmaceuticals Pte Ltd Introductory Comments - **Adj Prof (Dr) Raymond Chua**, CEO Health Sciences Authority - **Shanti Marlina Sibuea, PhD**, Acting Director of Drugs, Narcotics, Psychotropics, and Precursors Production Control, Indonesian Food and Drug Authority (BPOM) Panel **- Adj Prof (Dr) Raymond Chua**, HSA **- Azuana binti Ramli, RPh, PhD,** Ministry of Health, Malaysia - **Shanti Marlina Sibuea, PhD**, Indonesian Food and Drug Authority (BPOM) **- Sia Lee Yoong,** GSK
3.40 - 4.10 pm	**Break**

4.10 -5.40 pm	**Session 4- China Townhall** **Advancing the Ecosystem: Integrating Regulatory Reform, Inspection Excellence, and Clinical Quality in China**
	The China Townhall will deliver the latest updates on the evolving trends in pharmaceutical innovation, newly launched regulatory initiatives, progress in drug inspection, drug analysis, and clinical trial quality. This session will feature distinguished speakers from the National Medical Products Administration (NMPA) and its affiliated organizations, including the Center for Drug Inspection (CDI), the National Institute for Food and Drug Control (NIFDC), as well as investigator representatives. These speakers will share valuable insights into China's regulatory advancements, drug inspection practices, PIC/S updates, and the ongoing efforts to enhance clinical trial quality—all aimed at accelerating the development of innovative drugs both in China and globally. By integrating perspectives from all invited speakers, this session is designed to provide comprehensive information that will deepen participants' understanding of China's evolving regulatory landscape and drug development ecosystem, while fostering opportunities for international collaboration

Session Moderators

Xiaojun Yan,
Strategic Advisor, DIA China

Jingping Yeo,
Chair, Advisory Committee, DIA Singapore

4.10 - 4.15 pm	Opening Remarks
4.15 - 4.25 pm	Opening Address
	Feng ZHU, Director of Cooperation Division, China Center for Medical Products International Exchange (CCMPIE)
4.25 - 4.40 pm	Updates on China's Drug Regulatory Reform
	Lingchao ZHANG, Deputy Director, General Affairs Division, Drug Registration Department, NMPA
4.40 - 4.50 pm	Drug Inspection Update I
	Yuan WANG, Director of Inspection Division I, Center for Drug Inspection, NMPA
4.50 - 5.00 pm	Drug Inspection Update II
	Jiafei CUI, Senior Inspector and Inspection Team Leader, Center for Drug Inspection, NMPA
5.00 - 5.15 pm	CDE Updates
	Fan ZHANG, Pharmacist in charge, Business Management Division, Center for Drug Evaluation (CDE), NMPA
5.15 - 5.30 pm	National Medical Centers Empowering Innovative Drug R&D: From the Origin to the Main Battlefield
	Yifeng SHEN, MD, PhD, GCP Director and IRB member, Shanghai Mental Health Center
5.30 - 5.45 pm	Q&A
	Moderator **- Ling SU, PhD,** DIA Global Fellow Strategic Advisor to Chief Scientific Officer, China R&D, Sanofi / Venture Partner, LAV **Panelist** **- Lingchao ZHANG,** NMPA **- Yuan WANG,** NMPA **- Jiafei CUI,** NMPA **- Fan ZHANG,** NMPA **- Yifeng SHEN, MD, PhD**, Shanghai Mental Health Center
5.45 - 6.00 pm	**Closing**
6.30 - 8.30 pm	**Networking Dinner**

DIA

Thank You Supporters

PharmaKnowl Consulting

propharma

Asteri

ONCOSHOT

PRECISION for medicine

EverArc Pharmaceuticals

Uppsala Monitoring Centre

SINGAPORE CLINICAL RESEARCH PROFESSIONALS

SingHealth
Defining Tomorrow's Medicine

meditrade Solutions International

atvacare